|
| Monday, November 20, 2017 |
|
|
Eisai: Antiepileptic Drug Fycompa Regularly Available Again in Germany from December |
| Eisai Co., Ltd. has announced that its German sales company Eisai GmbH and the National Association of Statutory Health Insurance Funds (GKV-Spitzenverband) have agreed on a reimbursement price for Eisai's antiepileptic drug (AED) Fycompa (perampanel). more info >> |
|
| Monday, November 6, 2017 |
|
|
New Data From Long-Term Extension of Phase 1B Study of Investigational Alzheimer's Disease Treatment Aducanumab Presented at 10th Clinical Trials on Alzheimer's Disease |
| Eisai Co., Ltd. announced today that Biogen Inc. (Nasdaq: BIIB) presented new data from the long-term extension (LTE) of its ongoing Phase 1b study of aducanumab, an investigational treatment for Alzheimer's disease at the 10th Clinical Trials on Alzheimer's Disease (CTAD) meeting, Boston, Massachusetts, United States, from November 1 to 4. more info >> |
|
| Tuesday, October 31, 2017 |
|
|
Eisai's New Drug Application of Anticancer Agent Lenvatinib for Hepatocellular Carcinoma Accepted in China |
| Eisai Co., Ltd. announced that the China Food and Drug Administration (CFDA) has accepted for review a New Drug Application (NDA) submitted for Eisai's in-house discovered and developed anticancer agent lenvatinib mesylate for use in the treatment of hepatocellular carcinoma (HCC) in China. more info >> |
|
|
Eisai to Present Latest Data at 10th Clinical Trials on Alzheimer's Diesase |
| Eisai Co., Ltd. announced today that the latest data on its oral dual orexin receptor antagonist lemborexant and its oral beta secretase cleaving enzyme (BACE) inhibitor elenbecestat(1) will be presented at the 10th Clinical Trials on Alzheimer's Disease (CTAD), taking place in Boston, the United States, from November 1 to 4. more info >> |
|
| Tuesday, October 24, 2017 |
|
|
Biogen and Eisai Expand Existing Collaboration Agreement to Develop and Commercialize Investigational Alzheimer's Disease Treatments Including Phase 3 Aducanumab |
| Eisai Co., Ltd. and Biogen Inc. announced today that the companies have expanded their existing agreement to jointly develop and commercialize investigational Alzheimer's disease treatments. more info >> |
|
| Friday, October 13, 2017 |
|
|
Eisai: Transfer of Rights to Anti-Rheumatic Agent Kolbet Tablets 25mg in Japan |
| Eisai Co., Ltd., Toyama Chemical Co., Ltd. of the Fujifilm Group and Taisho Pharmaceutical Co., Ltd. today that Eisai will acquire the marketing authorization and take over the marketing activities for anti-rheumatic agent KOLBET Tablets 25mg (generic name: iguratimod), based on an agreement between the companies. more info >> |
|
| Wednesday, October 11, 2017 |
|
|
Small and Easy to Take, Just One Tablet per Dose Eisai to Launch "Onji-No-Megumi" for Improving Forgetfulness in Middle Age and Beyond |
| Eisai Co., Ltd. will launch Onji-no-Megumi (category-3 OTC drug), a medicine for improving forgetfulness in middle age and beyond, on October 10 (Tuesday) at pharmacies and drugstores countrywide. more info >> |
|
| Wednesday, October 4, 2017 |
|
|
Eisai and Biotoscana Sign Exclusive Licensing Agreement for Latin America |
| Eisai Co., Ltd. announced today that its U.S. subsidiary, Eisai Inc., has signed an exclusive licensing agreement with Grupo Biotoscana for Eisai's oncology and neurology products in Latin America. more info >> |
|
| Tuesday, October 3, 2017 |
|
|
Sato Pharmaceutical and Eisai to Co-Promote New Oral Antifungal Agent Containing Active Ingredient Fosravuconazole in Japan |
| Sato Pharmaceutical Co., Ltd., Eisai Co., Ltd., and Seren Pharmaceuticals Inc. announced today that Sato Pharma and Eisai will co-promote a new triazole class oral antifungal agent (development code: BFE1224, "the agent") containing the active ingredient fosravuconazole L-lysine ethanolate ("fosravuconazole") in Japan, based on an agreement between the three companies. more info >> |
|
| Friday, September 29, 2017 |
|
|
Eisai Presents Results of Phase Iii Trial of Lenvima (Lenvatinib) in Unresectable Hepatocellular Carcinoma in Oral Session at 20th CSCO Annual Meeting |
| In the subpopulation analysis, lenvatinib demonstrated efficacy based on extension of Overall Survival (OS) compared to sorafenib (nominal P = 0.026), with improvements also observed in Progression Free Survival (PFS), Time to Progression (TTP) and Objective Response Rate (ORR) (see table below). more info >> |
|
|
|
